SK Bioscience, the biotech part of South Korea's SK Group, opened a new global research and development center to improve its vaccine research. The center, located in Songdo, a business district near Seoul, is also the company's new headquarters. The USD 255.7 million facility is the largest in South Korea dedicated to vaccine development.
This new center will allow SK Bioscience to handle the entire vaccine development process, from early research to testing, all in one place. This should help speed up the process and improve the quality of their work.
In other news, SK Bioscience reported a third-quarter profit of USD 14.8 million in November 2025, a big improvement from a loss the previous year. The company also met with Bill Gates to discuss global health projects, with Gates expressing hope that South Korea will play a bigger role in vaccine and health solutions worldwide.
This facility represents a significant milestone in the company’s vision to become a global leader in vaccine innovation and development, positioning SK Bioscience to better address both local and global healthcare challenges.
Executive Statement
According to Ahn Jae-young, chief executive officer, the move into the Songdo Global R&PD Centre is meaningful not merely as a relocation, but as the acquisition of critical infrastructure that enables the tangible execution of SK Bioscience’s mid- to long-term growth strategy.
